UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2016
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F x FORM 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
YES ¨ NO x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
On September 27, 2016, Summit Therapeutics plc issued a press release announcing that it has received Rare Pediatric Disease designation from the U.S. Food and Drug Administration for ezutromid in the treatment of Duchenne muscular dystrophy. The related press release is attached hereto as Exhibit 99.1.
The information in this Report on Form 6-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC | ||
By: | /s/ Erik Ostrowski | |
Erik Ostrowski | ||
Chief Financial Officer |
Date: September 28, 2016
EXHIBIT INDEX
Exhibit Number |
Description | |
99.1 | Press release dated September 27, 2016 |
Exhibit 99.1
Summit Therapeutics plc
(Summit or the Company)
SUMMIT RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDA FOR EZUTROMID IN TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Oxford, UK, 27 September 2016 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection, today announces it has received Rare Pediatric Disease designation from the US Food and Drug Administration (FDA) for ezutromid in the treatment of DMD. As a utrophin modulator, ezutromid has potential as a disease-modifying treatment for all patients with the fatal muscle wasting disease DMD, regardless of their underlying dystrophin gene mutation.
Rare Pediatric Disease designation builds upon the Fast Track and Orphan Drug designations which the FDA has already awarded to ezutromid, recognizing a significant unmet medical need in the treatment of DMD, said Glyn Edwards, Chief Executive Officer of Summit. We plan to leverage these regulatory advantages in the continued clinical development of ezutromid, which is currently in a Phase 2 clinical trial called PhaseOut DMD, to bring ezutromid to patients in need as quickly as possible.
The FDA defines Rare Pediatric Disease as a disease that primarily affects individuals aged from birth to 18 years and affects fewer than 200,000 persons in the US. Under the Rare Pediatric Disease Priority Review Voucher programme, a sponsor who receives an approval for a drug or biologic for a rare pediatric disease may qualify for a voucher which can be redeemed to receive a priority review of a subsequent marketing application for a different product. The Priority Review Voucher is requested at the time of the marketing application and awarded upon approval of the product. The voucher may only be used once, but may be sold or transferred an unlimited number of times. The Rare Pediatric Designation follows on the recently granted Fast Track designation by the FDA for ezutromid. The Rare Pediatric Priority Review Voucher programme is set to expire on 1 October 2016, although the US Congress is currently considering legislation to extend the programme. If the programme is not renewed, the FDA will no longer award pediatric vouchers to otherwise eligible sponsors.
About Utrophin Modulation in DMD
DMD is a progressive muscle wasting disease that affects around 50,000 boys and young men in the developed world. The disease is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles. There is currently no cure for DMD and life expectancy is into the late twenties. Utrophin protein is functionally and structurally similar to dystrophin. In preclinical studies, the continued expression of utrophin has a meaningful, positive effect on muscle performance. Summit believes that utrophin modulation has the potential to slow down or even stop the progression of DMD, regardless of the underlying dystrophin gene mutation. Summit also believes that utrophin modulation could potentially be complementary to other therapeutic approaches for DMD. The Companys lead utrophin modulator, ezutromid, is an orally administered, small molecule. DMD is an orphan disease, and the US Food and Drug Administration and the European Medicines Agency have granted Orphan Drug designation to ezutromid. Orphan drugs receive a number of benefits including additional regulatory support and a period of market exclusivity following approval. In addition, ezutromid has been granted Fast Track designation and Rare Pediatric Disease designation by the FDA.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit |
||||
Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) |
Tel: | +44 (0)1235 443 951 +1 617 225 4455 | ||
Cairn Financial Advisers LLP |
||||
(Nominated Adviser) Liam Murray / Tony Rawlinson |
Tel: | +44 (0)20 77148 7900 | ||
N+1 Singer |
||||
(Broker) Aubrey Powell / Jen Boorer |
Tel: | +44 (0)20 7496 3000 | ||
MacDougall Biomedical Communications |
||||
(US media contact) Chris Erdman / Karen Sharma |
Tel: | +1 781 235 3060 | ||
cerdman@macbiocom.com / ksharma@macbiocom.com | ||||
Consilium Strategic Communications |
Tel: | +44 (0)20 3709 5700 | ||
(Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville |
summit@consilium-comms.com
| |||
Forward-looking Statements
Any statements in this press release about Summits future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of Summits product candidates, the therapeutic potential of Summits product candidates, and the timing of initiation, completion and availability of data from clinical trials, and other statements containing the words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would, and similar expressions, constitute forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summits foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the Risk Factors section of filings that Summit makes with the Securities and Exchange Commission including Summits Annual Report on Form 20-F for the fiscal year ended January 31, 2016. Accordingly readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent Summits views only as of the date of this release and should not be relied upon as representing Summits views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking statements included in this press release.
-END-
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